Hostile Takeover

The case of International Paper's hostile offer for forest products company Temple-Inland is a lesson in why you shouldn't just jump on a hot takeover stock. IP offered Temple 45% more than its market value, and got shot down. Investors who hoped to cash in are likely to be stuck with loses.

It seems that months of merger talks between French pharma Sanofi-Aventis and U.S. biotech Genzyme have entered the home stretch. This week, Sanofi is expected to offer $74 a share for Genzyme, with an option included potentially worth $5 to $6 a share.

The U.S. biotech is holding an analyst and investor meeting focused on the commercial potential of its multiple sclerosis drug Campath. The goal: to convince Paris-based Sanofi-Aventis to raise its hostile takeover offer in a battle that has now gone on for five months.

In a surprise decision by a government that has historically favored foreign investment, Canada has rejected a foreign takeover bid for Saskatchewan-based Potash Corp. Australian mining company BHP Billiton had offered $38.6 billion in what would have been the world's largest corporate acquisition this year.

There's a new plot twist in the takeover battle between French pharmaceutical giant Sanofi-Aventis and U.S. drugmaker Genzyme. A regulatory filing made by Genzyme on Thursday claims Sanofi may be willing to go much higher than its current $69 bid -- a claim the French company disputes.

After months of courting U.S. drugmaker Genzyme, French pharmaceutical company Sanofi-Aventis launched a hostile bid valued at approximately $18.5 billion, or $69 a share, for all outstanding shares of Genzyme common stock.

Air Products & Chemicals (APD) has raised its bid for Airgas (ARG) to $65.50 a share in an all-cash offer. The latest offer represents a 50% premium above Airgas' closing stock price on Feb. 4, the day prior to Air Products submitting its first acquisition plan, Air Products said Monday in a written statement.

Lions Gate Entertainment shares jumped some 12.5% to around $7.30 Tuesday after billionaire activist investor Carl Icahn raised his hostile bid for the studio to $7.50 per share in cash, up from the previous offer of $6.50 a share. Lions Gate's board said it will review the offer.

Pharmaceutical giant Sanofi-Aventis is unwilling to pay more than $70 a share in its bid to buy biotech firm Genzyme, media outlets reported Wednesday. If a deal can't be reached, the French drugmaker may consider alternative takeover targets.

Potash Corp. of Saskatchewan Inc. said Monday that its board voted unanimously to reject BHP Billiton's hostile $38.5 billion takeover offer as it doesn't reflect the strong growth the company believes it is poised to enjoy.